inmune
bio
presents
preliminary
phase
data
international
conference
alzheimer
drug
discovery
la
jolla
globe
newswire
inmune
bio
nasdaq
inmb
company
immunology
company
focused
developing
treatments
harness
patient
innate
immune
system
fight
disease
today
announced
cj
barnum
phd
head
neurosciences
present
data
ongoing
biomarker
directed
phase
ib
study
neuroinflammation
patients
alzheimer
disease
talk
entitled
phase
study
ad
patients
given
today
et
part
year
virtual
international
conference
alzheimer
drug
discovery
meeting
trial
continues
enroll
patients
additional
data
phase
ib
study
presented
near
future
neuroinflammation
plays
important
role
pathophysiology
alzheimer
disease
said
cj
barnum
phd
head
neurosciences
inmune
bio
preliminary
data
albeit
small
number
patients
demonstrate
given
via
subcutaneous
injection
decreases
neuroinflammation
arcuate
fasciculus
white
matter
tract
critical
proper
use
white
matter
free
water
wmfw
novel
biomarker
inflammation
measured
using
neuroimaging
functional
mri
increases
wmfw
biomarkers
occur
alzheimer
patients
disease
progresses
preliminary
data
first
patients
showed
treatment
decreased
wmfw
average
arcuate
fasciculus
range
selective
inhibitor
soluble
tumor
necrosis
factor
stnf
key
inflammatory
cytokine
implicated
causing
neuroinflammation
patients
neurologic
disease
including
treatment
resistant
depression
alzheimer
disease
potentially
neurodegenerative
diseases
phase
ib
open
label
study
enroll
patients
biomarkers
inflammation
alzheimer
disease
patients
treated
weeks
multiple
measures
neuroinflammation
studied
including
biomarkers
inflammation
blood
csf
breath
well
neuroimaging
biomarkers
studied
mri
behavioral
commonly
seen
ad
patients
depression
aggression
apathy
anhedonia
sleep
disorders
measures
cognitive
decline
measured
part
trial
due
small
size
short
duration
variable
disease
status
time
enrollment
changes
cognitive
function
primary
endpoints
use
novel
biomarkers
hallmark
inmune
bio
clinical
development
programs
said
rj
tesi
md
ceo
inmune
bio
use
biomarkers
may
allow
smarter
smaller
faster
clinical
trials
patients
neurodegenerative
inhibitor
tumor
necrosis
factor
tnf
acts
differently
currently
existing
tnf
inhibitors
neutralizes
soluble
tnf
stnf
without
affecting
tnf
tmtnf
tnf
receptors
could
substantial
beneficial
effects
patients
alzheimer
disease
decreasing
neuroinflammation
information
importance
targeting
neuroinflammation
brain
improve
cognitive
function
restore
neuronal
communication
visit
section
inmune
bio
website
inmune
bio
inmune
bio
publicly
traded
nasdaq
inmb
biotechnology
company
focused
developing
treatments
target
innate
immune
system
fight
disease
inmune
bio
two
product
platforms
product
platform
utilizes
technology
selectively
neutralize
soluble
tnf
key
driver
innate
immune
dysfunction
mechanistic
target
many
diseases
currently
developed
complications
cancer
alzheimer
treatment
resistant
depression
nash
natural
killer
cell
priming
platform
includes
aimed
priming
patient
nk
cells
eliminate
minimal
residual
disease
patients
cancer
inmune
bio
product
platforms
utilize
precision
medicine
approach
treatment
wide
variety
hematologic
malignancies
solid
tumors
chronic
inflammation
learn
please
visit
forward
looking
statements
company
clinical
trials
early
stages
assurance
specific
outcome
achieved
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
contained
herein
based
current
expectations
subject
number
risks
uncertainties
actual
results
timing
certain
events
circumstances
may
differ
materially
described
statements
result
risks
uncertainties
livnate
inkmune
still
clinical
trials
preparing
start
clinical
trials
approved
assurance
approved
specific
results
achieved
two
platforms
beginning
clinical
trials
assurance
success
trials
factors
could
cause
actual
future
results
differ
materially
current
expectations
include
limited
risks
uncertainties
relating
company
ability
produce
drug
clinical
trials
availability
substantial
additional
funding
company
continue
operations
conduct
research
development
clinical
studies
future
product
commercialization
company
business
research
product
development
regulatory
approval
marketing
distribution
plans
strategies
factors
identified
described
detail
company
filings
securities
exchange
commission
including
company
annual
report
form
company
quarterly
reports
form
company
current
reports
form
company
assumes
obligation
update
statements
order
reflect
event
circumstance
may
arise
date
release
inmune
bio
contact
david
moss
cfo
dmoss
investor
contact
chuck
padala
lifesci
advisors
chuck
media
contact
meredith
sosulski
lifesci
communications
msosulski
